TCN 201 is a potent, selective and non-competitive antagonist of GluN1/GluN2A NMDA receptor, with a pIC₅₀ of 6.8. TCN 201 is selective for GluN1/GluN2A NMDA receptor over GluN1/GluN2B NMDA receptor (pIC₅₀<4.3).

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

3-Chloro-4-fluoro-N-[(4-{[2-(phenylcarbonyl)hydrazino]carbonyl}phenyl)methyl]benzenesulfonamide; N-[[4-(benzamidocarbamoyl)phenyl]methyl]-3-chloro-4- fluorobenzenesulfonamide

white to beige powder

DMSO : 250 mg/mL (541.25 mM; Need ultrasonic)

TCN 201 (compound 1) is selective for GluN1/GluN2A NMDAR over GluN1/GluN2B NMDAR, with pIC50s of 6.8 and <4.3, respectively.
TCN 201 (10 μM) produces only slight inhibition of GluN1/GluN2B NMDAR-mediated currents in oocytes.
TCN 201 (10-30 μM) antagonism of NMDAR-mediated responses is both subtype- and glycine-dependent and more potent than TCN 213 in oocytes.

TCN-201 (10 mg/kg; i.p.) is ineffective in CSD blood-oxygen level-dependent (BOLD) response in rats.

TCN 213 is an NMDA receptor antagonist that has been reported to be selective for NMDA ε 1 (NR1/NR2A) over NR1/NR2B.

An NMDA receptor antagonist that has been reported to be a selective for NR1/NR2A over NR1/NR2B

95%

Store at 4° C

Solid

Crystalline powder

~1.3 g/cm³ (Predicted)

~252.76° C (Predicted)

~585.98° C (Predicted)

n²⁰_D 1.62 (Predicted)

Soluble in DMSO (75 mM), and ethanol (10 mM).

MFCD04788042

2608149